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Diabetic nephropathy is one of the most important 
complication of diabetes mellitus[4,5] and MF has been 
widely used for treatment of type 2 diabetes.[3,4] Thus 
according to our results and those published by Taheri 
et al., MF protects against tubular injury by restoring 
the biochemical alterations and modulation of oxidative 
stress on the tubules.[1,2] Moreover, according to the 
study by Kim et al., MF protects podocytes in diabetic 
nephropathy,[3] while in diabetic nephropathy, there 
is also tubular cell injury due to glocosuria.[3‑7] These 
findings can more potentiate the clinical use of MF in 
the prevention of diabetic nephropathy. In this regard, 
to understand the MF‑nephroprotective properties 
better, more experimental rat model or clinical studies 
are suggested.
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Sir,
Recently, we published an article in J Res Med Sci, entitled 
“Ameliorative effects of metformin on renal histologic 
and biochemical alterations of gentamicin‑induced renal 
toxicity in Wistar rats.”[1] In this article, it is concluded that 
metformin (MF) may prevent or ameliorate GM‑induced 
acute renal failure, and therefore, it might be beneficial 
in patients under treatment with this medicine.[1] In this 
letter, we would like to point out a few points about 
the mentioned conclusion. In an agreement with our 
findings, Taheri et al. recently conducted a study on 
the effects of MF on renal function and structure after 
unilateral ischemia–reperfusion in rat. They found that 
MF provided some renal protection against ischemia 
and reperfusion (I/R) induced injury to the rats kidney. 
They concluded that MF with activation of adenosine 
monophosphate‑activated protein kinase (AMPK) and 
endothelial nitric oxide synthase have tissue protective 
effects.[2] More recently, Kim et al. performed a study 
using MF (350 mg/kg/day) for spontaneously diabetic 
Torii (SDT) rats for 17 weeks. They examined blood 
glucose, glycated hemoglobin and albuminuria, kidney 
histopathology, renal 8‑hydroxydeoxyguanosine levels, 
and also apoptosis. They found that treatment of SDT 
rats with MF restored podocyte loss. They suggested 
that diabetes‑induced podocyte loss in diabetic 
nephropathy could be suppressed by MF, through the 
repression of oxidative injury.[3]
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